Many individuals who initiate GLP-1 receptor agonists like Semaglutide or Tirzepatide often reflect on what they wish they had known or done beforehand. One of the frequent regrets is not having a comprehensive medical consultation prior to starting therapy, especially in the age of telehealth where quick prescriptions may bypass important screenings. Patients have reported wishing they had undergone assessments such as a thorough sleep study, especially since conditions like moderate to severe obstructive sleep apnea (OSA) can influence treatment efficacy and overall health. For example, Zepbound, another FDA-approved medication for OSA, highlights the importance of recognizing coexisting conditions before beginning GLP-1 treatment. Another common oversight involves understanding the impact of GLP-1 medications on diabetes management. Many regret not confirming their diabetes diagnosis and related markers with their healthcare provider first, which can affect dosing and monitoring plans. Furthermore, users often wish they had set realistic expectations regarding side effects, weight loss timelines, and lifestyle adjustments needed alongside the medication. Proper patient education on these factors can improve adherence and satisfaction. Lastly, some patients express frustration about missing the opportunity to document their baseline health status prior to medication initiation. This documentation can be critical for assessing progress and potential side effects accurately. In summary, before starting GLP-1 medications like Semaglutide or Tirzepatide, it is advisable to: - Consult your healthcare provider thoroughly, including in-person evaluations when possible. - Complete relevant diagnostic tests such as sleep studies if indicated. - Confirm and understand your diabetes or metabolic health status. - Set realistic treatment goals and expectations. - Document your baseline health condition to track changes effectively. By addressing these aspects early, patients can avoid common regrets and enhance their experience and outcomes with GLP-1 therapies.